Cardiovascular Business spoke with cardiologist Daniel Judge, MD, about the long-term benefits of acoramidis, a new drug therapy that just received FDA approval to treat transthyretin amyloid cardiomyopathy.
Deepak Bhatt, MD, MPH, MBA, spoke to Cardiovascular Business about the growing importance of evaluating coronary inflammation in heart patients. There has been an explosion of interest in this area since the FDA's 2023 clearance of colchicine.
Hadley Wilson, MD, spoke to Cardiovascular Business at the three-day event to discuss key late-breaking studies and trends. Topics included new drug treatments, AI and much more.
Early detection of cardiac amyloidosis is leads to the best outcomes, but it is often missed until later stages. AI is being developed to help detect these patients earlier using ECG and echo.
Researchers explored data from 23 different studies, identifying a “positive and almost linear association” between alcohol consumption and hypertension.
Paul Zei, MD, discusses late-breaking data from the REAL-AF Registry, which looked at the short- and long-term outcomes of radiofrequency ablation in paroxysmal and persistent atrial fibrillation.
Researchers developed an advanced AI model capable of extracting measurements from unprocessed CT images in seconds. It then uses those data to evaluate the patient's mortality risk if they underwent TAVR.
Devi Nair, MD, director of cardiac electrophysiology with St. Bernard's Heart and Vascular Center, discussed her experience using a new-look Medtronic pulsed field ablation (PFA) system to treat persistent AFib.
Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.
